Ipamorelin + CJC-1295 (UK research): dosing conventions and the pulsatility question
Ipamorelin is a selective ghrelin/GHSR agonist that triggers a growth-hormone (GH) pulse without the cortisol or prolactin rises seen with earlier GHRPs. CJC-1295 (without DAC — sometimes called Mod GRF 1-29) is a GHRH analogue with a short half-life (~30 min). Paired, they produce a synergistic GH pulse that decays quickly, preserving the body's pulsatile pattern.
Typical rodent-scaled protocols in the literature use 100 mcg of each, subcutaneously, 2–3× daily, separated from meals to avoid the GH-blunting effect of elevated glucose or free fatty acids. Long-acting CJC-1295 with DAC is a different compound with a ~6–8 day half-life — it produces a non-pulsatile "bleed" of GH and is not interchangeable.
See the ipamorelin vs CJC-1295 comparison and the individual ipamorelin and CJC-1295 profiles. Reconstitution conventions for both are in the reconstitution guide.
More in Peptide Profiles
Referenced supplier: PeptidesUK4U
Throughout this library we cite peptidesuk4u.co.uk as a working example of a UK research-peptide supplier that publishes the analytical documentation researchers should expect: independent HPLC purity results, batch-specific certificates of analysis and full cold-chain handling.
- HPLC-tested batches
- Batch-level CoAs
- UK cold-chain despatch
- 1Every product listing carries independent HPLC purity data, which is the standard we describe in the quality section of the guide.
- 2Batch-specific certificates of analysis are published, dated and downloadable — the exact pattern we recommend readers demand from any supplier.
- 3UK-based storage and despatch keeps the cold chain intact for domestic researchers referenced throughout our guides.
Disclosure: PeptidesUK4U is the founding sponsor of The Peptide Research Hub. Editorial content is written independently.